Recent National and Regional Drug Reforms in Sweden Björn WettermarkBrian GodmanVittorio Bertelé Current Opinion 22 September 2012 Pages: 537 - 550
Pharmaceutical Risk-Sharing Agreements Joseph P. CookJohn A. VernonRichard Manning Current Opinion 22 September 2012 Pages: 551 - 556
Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit? Jon JureidiniBarbara MintzesMelissa Raven Commentary 22 September 2012 Pages: 557 - 566
Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes Stefan VegterCornelis BoersmaMaarten J. Postma Review Article 22 September 2012 Pages: 569 - 587
Future Drug Prices and Cost-Effectiveness Analyses Martin Hoyle Original Research Article 22 September 2012 Pages: 589 - 602
Generic Entry, Reformulations and Promotion of SSRIs in the US Haiden A. HuskampJulie M. DonohueRichard G. Frank Original Research Article 22 September 2012 Pages: 603 - 616
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK Ray GaniGavin GiovannoniJohn Kerrigan Original Research Article 22 September 2012 Pages: 617 - 627